Feb. 27 at 7:51 PM
$RAPT Equity Corporate Actions Alert #2026 - 124
Information Regarding the Tender Offer of RAPT Therapeutics, Inc. (RAPT)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-124
The tender offer by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK PLC to acquire all of the outstanding common stock of RAPT Therapeutics, Inc. (RAPT) is scheduled to expire one minute after 11:59 p.m. ET, on March 2, 2026, unless extended or terminated. If successful, the subsequent merger is tentatively scheduled to close prior to the market open on March 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on March 2, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (March 3rd) and will be suspended effective March 4, 2026.
RAPT shareholders will receive
$58 per share at closing.
